Enforce FD&C Act; Don't Stretch It
This article was originally published in RPM Report
The new FDA senior leadership duo of Hamburg and Sharfstein are sending signs that they are ready to find some object lessons for high-visibility enforcement actions. A former FDA chief counsel and Just Department chief of staff warn that the agency should pict its targets carefully. Enforcing regulatory priorities instead of regulatory law can get the agency into difficult situations.
You may also be interested in...
The long awaited head-to-head trial of Avastin vs. Lucentis in macular degeneration has finally reported results. It pits a $1,500 a dose therapy against a $50, unapproved alternative that most providers think is just as good. We just had that debate over Makena. Recent comments by FDA’s top drug review official suggest there may be another connection.
An interview with newly confirmed FDA Commissioner Margaret Hamburg.
Let The Sunshine In: Health Care Reform Law Mandates Public Disclosure of Financial Ties Between Industry and Physicians
The "physician payments sunshine" provisions of the recently enacted health care reform legislation may chill relations between industry and physicians. They also are likely to impose significant costs on drug and device manufacturers.